Could Larimar be closer to changing the Friedreich’s ataxia treatment landscape?
Larimar’s rolling BLA submission and long-term nomlabofusp data strengthen the case for a potential disease-modifying Friedreich’s ataxia therapy.
Larimar’s rolling BLA submission and long-term nomlabofusp data strengthen the case for a potential disease-modifying Friedreich’s ataxia therapy.